Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Status:
Completed
Trial end date:
2016-02-18
Target enrollment:
Participant gender:
Summary
The primary objective was to determine the effect of treatment with romosozumab versus
placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the
lumbar spine in postmenopausal women with low bone density.